Latest Insider Transactions at Neumora Therapeutics, Inc. (NMRA)
This section provides a real-time view of insider transactions for Neumora Therapeutics, Inc. (NMRA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Neumora Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Neumora Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 28
2023
|
Arch Venture Partners Xii, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
41,951
+0.55%
|
$545,363
$13.38 P/Share
|
|
Sep 27
2023
|
Arch Venture Partners Xii, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
24,504
+0.64%
|
$294,048
$12.31 P/Share
|
|
Sep 27
2023
|
Kristina Burow |
BUY
Open market or private purchase
|
Indirect |
24,504
+0.64%
|
$294,048
$12.31 P/Share
|
|
Sep 26
2023
|
Arch Venture Partners Xii, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
34,000
+0.9%
|
$374,000
$11.73 P/Share
|
|
Sep 26
2023
|
Kristina Burow |
BUY
Open market or private purchase
|
Indirect |
34,000
+0.9%
|
$374,000
$11.73 P/Share
|
|
Sep 25
2023
|
Kristina Burow |
BUY
Open market or private purchase
|
Indirect |
60,740
+0.81%
|
$668,140
$11.23 P/Share
|
|
Sep 25
2023
|
Arch Venture Partners Xii, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
60,740
+0.81%
|
$668,140
$11.23 P/Share
|
|
Sep 22
2023
|
Kristina Burow |
BUY
Open market or private purchase
|
Indirect |
40,000
+1.08%
|
$440,000
$11.14 P/Share
|
|
Sep 22
2023
|
Arch Venture Partners Xii, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
40,000
+1.08%
|
$440,000
$11.14 P/Share
|
|
Sep 19
2023
|
Fmr LLC |
BUY
Conversion of derivative security
|
Indirect |
3,712,624
+35.19%
|
-
|
|
Sep 19
2023
|
Kristina Burow |
BUY
Open market or private purchase
|
Indirect |
1,500,000
+29.27%
|
$25,500,000
$17.0 P/Share
|
|
Sep 19
2023
|
Kristina Burow |
BUY
Conversion of derivative security
|
Indirect |
17,424,704
+44.34%
|
-
|
|
Sep 19
2023
|
Kristina Burow |
BUY
Conversion of derivative security
|
Direct |
13,620
+50.0%
|
-
|
|
Sep 19
2023
|
Arch Venture Partners X, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
3,000,000
+29.27%
|
$51,000,000
$17.0 P/Share
|
|
Sep 19
2023
|
Arch Venture Partners X, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
34,849,408
+44.34%
|
-
|
|
Sep 19
2023
|
Henry O Gosebruch President & CEO |
BUY
Open market or private purchase
|
Indirect |
15,000
+50.0%
|
$180,000
$12.62 P/Share
|
|
Sep 19
2023
|
Amgen Inc |
BUY
Open market or private purchase
|
Direct |
1,764,705
+4.75%
|
$29,999,985
$17.0 P/Share
|
|
Sep 19
2023
|
Amgen Inc |
BUY
Conversion of derivative security
|
Direct |
33,603,948
+50.0%
|
-
|
|
Sep 14
2023
|
Robert A. Lenz Head of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
352,941
+50.0%
|
-
|